New Market Report Now Available: France Pharmaceuticals & Healthcare Report Q2 2011

Recently published research from Business Monitor International, "France Pharmaceuticals & Healthcare Report Q2 2011", is now available at Fast Market Research
Spread the Word
Listed Under

* Healthcare
* Pharmaceutical
* Drug
* Governments
* Deficit
* Security
* French
* Rewards
* Attempt
* Social

* Health
* Medical
* Research

* Massachusetts - US

April 26, 2011 - PRLog -- In our latest proprietary Pharmaceuticals & Healthcare Business Environment Ratings (BER), France remains ranked fourth out of ten Western European countries. Globally, France ranks eighth in Q211, which is largely illustrative of its large overall size, high per capita use of pharmaceuticals and its advanced regulatory environment. However, the coming few years are expected to be challenging for research-based drugmakers in particular, given patent expirations and the wide-ranging cost-containment measures impacting healthcare and pharmaceutical spending, both in France, and the wider region.

The French drug market is large, calculated at EUR29.5bn (US$39.2bn) in 2010, even though the figures represent a year-on-year (y-o-y) decline of some 2.2% in local currency terms. Over the five-year forecast period to 2015, we calculate that the market will post a compound annual growth rate (CAGR) of -1.75% in local currency, or -2.96% in US dollar terms. While the subsequent years will provide more opportunities for the growth of personalised medicine and the launch of novel drugs, we still expect tenyear CAGRs to barely make it out of the negative territory, coming in at 0.68% and 0.06% in local currency and US dollar terms, respectively.

As has been the case in many other European countries, the French authorities have been forced to introduce fiscal austerities in a bid to contain debts. In fact, France's fiscal situation is among the worst in the EU, even after taking countries with high debt and deficit levels into consideration. As a result, areas of government spending, including healthcare and pharmaceuticals, have been targeted by costcontainment measures, including reductions in drug prices. We also believe that more measures will have to be announced over the coming months, as the government attempts to meet its targets. Moreover, over the coming ten years, the French economy will be characterised by weak growth, as both the private and public sectors focus on paying down debt accumulated during the past decade.

In light of an increasingly difficult operating environment at home, French drugmakers are continuing to target overseas markets and also alternative sources of growth. To this end, in February 2011, leading French pharmaceutical player Sanofi-Aventis and US biotechnology company Genzyme entered an agreement under which the former will acquire the latter. Christopher A. Vienbacher, CEO of Sanofi- Aventis, said: "This agreement with Genzyme is both consistent with our long-term strategy and creates significant long-term value for our shareholders. This transaction will create a meaningful new growth platform for Sanofi-Aventis while expanding our footprint in biotechnology."

For more information or to purchase this report, go to:

Report Table of Contents:

SWOT Analysis
- France Pharmaceuticals And Healthcare Industry SWOT
- France Political SWOT
- France Economic SWOT
- France Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Western Europe Pharmaceutical Business Environment Ratings for Q211
- Rewards
- Risks
France - Market Summary
Regulatory Regime
- Intellectual Property Developments
- Counterfeit Drugs
- Pricing and Reimbursement Issues
- Table: France Reimbursement Categories
- Evaluation of Treatments
- Recent Pricing and Reimbursement Developments
- OTC Market Developments
Industry Trends And Developments
- Epidemiology
- Table: Disease Burden In Western Europe
- Public Health Issues
- Prescribing Habits
- Healthcare Financing
- Research and Development (R&D)
- Biotechnology Sector
- Clinical Trials
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: France - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Product Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports and Imports Indicators 2007-2015
- Other Healthcare Data and Forecasts
- Key Risks to BMI's Forecasts
Competitive Landscape
- Table: French Pharmaceutical Companies According To Market Capitalisation
- Recent Company Developments
- Multinational Companies
- Wholesale Sector
- Pharmacy Sector
Company Monitor
- Indigenous Companies
- Sanofi-Aventis
- Servier
- Ipsen
- Leading Multinational Manufacturers
- Pfizer
- GlaxoSmithKline (GSK)
- Novartis
- Merck & Co
Country Snapshot: France Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education and Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market and Spending Power
- Table: Employment Indicators, 2000-2005
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceuticals Business Environment Ratings
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:*** Email Verified
Tags:Healthcare, Pharmaceutical, Drug, Governments, Deficit, Security, French, Rewards, Attempt, Social
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Daily News
Weekly News

Like PRLog?
Click to Share